Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 19/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | SNCA | P37840 | 1/20 | 0.60 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12808066 | 1.00 | APP (0.70) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL4162869 | 0.93 | APP (0.64) | APPMAPTSNCASULT1A1 | |
| SCHEMBL4008927 | 0.93 | APP (0.64) | APPMAPTSNCASULT1A1 | |
| SCHEMBL4162128 | 0.93 | APP (0.64) | APPMAPTSNCASULT1A1 | |
| SCHEMBL4154609 | 0.93 | APP (0.64) | APPMAPTSNCASULT1A1 | |
| SCHEMBL21140958 | 0.91 | APP (0.63) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL18726375 | 0.89 | APP (0.71) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL14583703 | 0.89 | APP (0.71) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL24133654 | 0.87 | APP (0.65) | APPMAPTSNCASULT1A1MEN1 | |
| SCHEMBL22477303 | 0.87 | APP (0.65) | APPMAPTSNCASULT1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217920-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | PIRAMAL IMAGING SA (CH) | 2013-08-22 | — | — | US | disclosed |
| US-20120263646-A1 | IMAGING AGENTS AND THEIR USE FOR THE DIAGNOSTIC IN VIVO OF NEURODEGENERATIVE DISEASES, NOTABLY ALZHEIMER'S DISEASE AND DERIVATIVE DISEASES | GUERBET (FR) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217920-A1 | METHOD FOR PRODUCTION OF F-18 LABELED AMYLOID BETA LIGANDS | APP, APBA1, BACE1 | APP 1/4885MAPT 13/4885SNCA 9/4885 |
| US-20120263646-A1 | IMAGING AGENTS AND THEIR USE FOR THE DIAGNOSTIC IN VIVO OF NEURODEGENERATIVE DISEASES, NOTABLY ALZHEIMER'S DISEASE AND DERIVATIVE DISEASES | SNCA, PSEN2, CLN6 | APP 10/4885MAPT 4/4885SNCA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.